Thrombopoietin_NN
and_CC
its_PRP$
receptor_NN
._.

Thrombopoietin_NN
-LRB-_-LRB-
TPO_NN
-RRB-_-RRB-
,_,
the_DT
primary_JJ
physiological_JJ
regulator_NN
of_IN
platelet_NN
production_NN
,_,
was_VBD
initially_RB
thought_VBN
to_TO
be_VB
a_DT
lineage-specific_JJ
factor_NN
acting_VBG
predominantly_RB
on_IN
megakaryocytopoiesis_NN
._.

Detailed_JJ
studies_NNS
establish_VBP
that_IN
this_DT
cytokine_NN
mediates_VBZ
biological_JJ
effects_NNS
on_IN
a_DT
broad_JJ
spectrum_NN
of_IN
hematopoietic_JJ
progenitor_NN
cells_NNS
,_,
including_VBG
stem_NN
cells_NNS
._.

TPO_NN
is_VBZ
a_DT
hormone_NN
constitutively_RB
produced_VBN
mainly_RB
by_IN
the_DT
liver_NN
and_CC
kidney_NN
._.

Plasma_NN
TPO_NN
levels_NNS
are_VBP
regulated_VBN
by_IN
the_DT
platelet_NN
and_CC
megakaryocyte_NN
mass_NN
through_IN
Mpl_NN
receptor_NN
binding_NN
,_,
internalization_NN
and_CC
degradation_NN
._.

The_DT
Mpl_NN
receptor_NN
is_VBZ
a_DT
member_NN
of_IN
the_DT
hematopoietin_NN
receptor_NN
superfamily_NN
lacking_VBG
intrinsic_JJ
kinase_NN
activity_NN
._.

Upon_IN
ligand-induced_JJ
Mpl_NN
homodimerization_NN
,_,
the_DT
major_JJ
signaling_NN
events_NNS
for_IN
proliferation_NN
are_VBP
mediated_VBN
through_IN
the_DT
JAK2\/STAT5_NN
pathway_NN
,_,
while_IN
differentiation_NN
might_MD
occur_VB
through_IN
a_DT
prolonged_JJ
activation_NN
of_IN
the_DT
MAPK_NN
pathway_NN
._.

Preclinical_JJ
and_CC
clinical_JJ
studies_NNS
demonstrate_VBP
the_DT
potential_JJ
use_NN
of_IN
TPO_NN
in_IN
a_DT
variety_NN
of_IN
contexts_NNS
,_,
but_CC
it_PRP
is_VBZ
too_RB
early_JJ
to_TO
evaluate_VB
its_PRP$
benefit_NN
in_IN
reducing_VBG
platelet_NN
transfusion_NN
._.

